Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
10 Results Found
AHA Urges Administration to Grant Exceptions for Tariffs for Medications and Medical Supplies
The AHA asks President Trump to consider granting exceptions to the current and proposed tariffs for medical devices and pharmaceuticals made in Mexico, Canada and China that are essential to the provision of safe, effective care in America's hospitals, clinics, and other settings.
UPDATE: Product Allocations for U.S. IV Products – Hurricane Impact on Baxter’s North Cove, NC Facility
A follow-up to Baxter’s communication on December 13, 2024 regarding increases in allocations for several U.S. IV products,
AHA to President Urging the Administration to Take Action to Address IV Solution Supply Shortage as a Result of Helene
AHA letter to President Biden urging the Administration to take action to address IV solution supply shortage as a result of hurricane Helene.
AHA Comments on Senate Finance Committee’s Drug Shortage Draft Legislation
AHA thanks the Senate Committee on Finance for the opportunity to comment on its draft legislation, the “Drug Shortage Prevention and Mitigation Act.”
AHA Letter to Senate Subcommittee Leadership on Appropriations Priorities for FY 2025
AHA Senate letter regarding funding for health care programs for fiscal year (FY) 2025.
AHRMM LUC Comments to the FDA’s Draft Guidance for Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices
The AHRMM LUC members submitted comments and recommendations to the FDA's Draft Guidance for Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices. They recommend that information related to all Class I Medical Devices be included in the GUDID without exception.
AHRMM Comment Letter to FDA Regarding the Draft Guidance for Industry on the Global Unique Device Identification Database (GUDID)
Letter/Comment
On November 21, 2013, AHRMM submitted electronically
AHRMM Statement on Comparative Effectiveness
Letter/Comment
AHRMM supports the concept and use of Comparative Effectiveness Research (CER) to provide evidence-based data to help inform purchasing decisions.
AHRMM LUC Comments to the FDA’s Communications About the Safety of Medical Devices
The AHRMM LUC members submitted public comments and recommendations at the FDA's November 2020 meeting related to the need to include the UDI in the recall process. They highlighted the prototype recall database and electronic submission form, as well as survey data supporting its creation.
AHRMM Comment Letter to FDA RE: “Modernizing FDA’s Data Strategy”
In September 2019, FDA announced its Technology Modernization Actio